文献速递呼吸衰竭与机械通气儿科与产科急症

微创肺表面活性物质治疗后早产儿两年结局:OPTIMIST-A随机临床试验随访

Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论接受CPAP的25–28周早产儿中,MIST与假治疗相比未降低2岁时死亡或神经发育障碍发生率(36.3% vs 36.1%),但减少了呼吸疾病住院和喘息。

本研究为OPTIMIST-A随机临床试验的随访研究,纳入11个国家33个三级新生儿重症监护病房的486例25–28周、接受CPAP的早产儿,MIST组(n=242)经细导管给予猪肺磷脂α 200 mg/kg,对照组(n=244)接受假治疗。主要终点为2岁校正年龄死亡或中重度神经发育障碍,MIST组78例(36.3%)vs 对照组79例(36.1%),风险差0%(95%CI -7.6%至7.7%),RR 1.0(95%CI 0.81–1.24),无显著差异。次要呼吸结局有利于MIST组:呼吸疾病住院49例(25.1%)vs 78例(38.2%),RR 0.66(95%CI 0.54–0.81);家长报告喘息或呼吸困难73例(40.6%)vs 104例(53.6%),RR 0.76(95%CI 0.63–0.90)。结论:MIST未减少2岁时死亡或NDD,但降低了生后2年内不良呼吸结局。

要点

  • 在25–28周接受CPAP的早产儿中,MIST组2岁死亡或中重度NDD发生率为36.3%(78例),对照组为36.1%(79例),RR 1.0(95%CI 0.81–1.24),无显著差异。
  • MIST组呼吸疾病住院率为25.1%(49例),对照组为38.2%(78例),RR 0.66(95%CI 0.54–0.81),有利于MIST。
  • MIST组家长报告喘息或呼吸困难为40.6%(73例),对照组为53.6%(104例),RR 0.76(95%CI 0.63–0.90),有利于MIST。
  • MIST组经细导管给予猪肺磷脂α 200 mg/kg,对照组接受假治疗;随访数据收集于2022年12月9日完成。
  • 该复合结局的各组成部分在两组间无显著差异。

适用人群与场景

  • 胎龄25至28周、接受持续气道正压通气(CPAP)的早产儿,来自11个国家33个三级新生儿重症监护病房。

处置流程与药物剂量

  • MIST组经细导管给予外源性肺表面活性物质猪肺磷脂α 200 mg/kg;对照组接受假治疗。

研究设计与关键结果

  • 研究类型:随机临床试验的随访研究,临床医生和结局评估者设盲;共纳入486例早产儿,MIST组242例,对照组244例;453例有随访数据(中位胎龄27.3周;女性228例[50.3%]);关键次要结局数据可获取于434例婴儿。
  • 主要终点(2岁校正年龄死亡或中重度神经发育障碍):MIST组78例(36.3%)vs 对照组79例(36.1%),风险差0%(95%CI -7.6%至7.7%),RR 1.0(95%CI 0.81–1.24)。
  • 该复合结局的各组成部分在两组间无显著差异。
  • 呼吸疾病住院:MIST组49例(25.1%)vs 对照组78例(38.2%),RR 0.66(95%CI 0.54–0.81)。
  • 家长报告喘息或呼吸困难:MIST组73例(40.6%)vs 对照组104例(53.6%),RR 0.76(95%CI 0.63–0.90)。

证据类型、等级与局限

  • 证据类型:随机临床试验的随访研究(RCT随访)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受CPAP的呼吸窘迫综合征早产儿中,与假治疗相比,MIST未降低2岁时死亡或神经发育障碍的发生率,但接受MIST的婴儿生后2年内不良呼吸结局发生率较低。

指南或共识出处

  • OPTIMIST-A随机临床试验随访研究,JAMA;试验注册号ACTRN12611000916943。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The long-term effects of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome remain to be definitively clarified.

OBJECTIVE: To examine the effect of MIST on death or neurodevelopmental disability (NDD) at 2 years' corrected age.

DESIGN, SETTING, AND PARTICIPANTS: Follow-up study of a randomized clinical trial with blinding of clinicians and outcome assessors conducted in 33 tertiary-level neonatal intensive care units in 11 countries. The trial included 486 infants with a gestational age of 25 to 28 weeks supported with continuous positive airway pressure (CPAP). Collection of follow-up data at 2 years' corrected age was completed on December 9, 2022.

INTERVENTIONS: Infants assigned to MIST (n = 242) received exogenous surfactant (200 mg/kg poractant alfa) via a thin catheter; those assigned to the control group (n = 244) received sham treatment.

MAIN OUTCOMES AND MEASURES: The key secondary outcome of death or moderate to severe NDD was assessed at 2 years' corrected age. Other secondary outcomes included components of this composite outcome, as well as hospitalizations for respiratory illness and parent-reported wheezing or breathing difficulty in the first 2 years.

RESULTS: Among the 486 infants randomized, 453 had follow-up data available (median gestation, 27.3 weeks; 228 females [50.3%]); data on the key secondary outcome were available in 434 infants. Death or NDD occurred in 78 infants (36.3%) in the MIST group and 79 (36.1%) in the control group (risk difference, 0% [95% CI, -7.6% to 7.7%]; relative risk [RR], 1.0 [95% CI, 0.81-1.24]); components of this outcome did not differ significantly between groups. Secondary respiratory outcomes favored the MIST group. Hospitalization with respiratory illness occurred in 49 infants (25.1%) in the MIST group vs 78 (38.2%) in the control group (RR, 0.66 [95% CI, 0.54-0.81]) and parent-reported wheezing or breathing difficulty in 73 (40.6%) vs 104 (53.6%), respectively (RR, 0.76 [95% CI, 0.63-0.90]).

CONCLUSIONS AND RELEVANCE: In this follow-up study of a randomized clinical trial of preterm infants with respiratory distress syndrome supported with CPAP, MIST compared with sham treatment did not reduce the incidence of death or NDD by 2 years of age. However, infants who received MIST had lower rates of adverse respiratory outcomes during their first 2 years of life.

TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000916943.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Dargaville PA, Kamlin COF, Orsini F, et al. Two-Year Outcomes After Minimally Invasive Surfactant Therapy in Preterm Infants: Follow-Up of the OPTIMIST-A Randomized Clinical Trial. JAMA. 2023. PMID: 37695601. doi:10.1001/jama.2023.15694

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。